CluePoints' unnamed top-10 pharma partner to present results at SCDM 2026

When a top-10 pharmaceutical company agrees to present live production results from a new AI-driven clinical data review platform at an industry conference, it signals more than a product launch—it marks a potential shift in how the entire sector handles data oversight.

CluePoints has quietly released three artificial intelligence capabilities—Intelligent Query Detection (IQD), Medical and Safety Review (MSR), and Intelligent Medical Coding (IMC)—that were built and rigorously tested within the live portfolio of an unnamed top-10 pharma partner before becoming generally available.

The partner’s data management leadership is now scheduled to present those production results at the SCDM 2026 Annual Conference in Raleigh, September 14 through 17, rather than a pre-launch proof of concept.

The stakes are underscored by two figures buried in the launch details: IMC targets up to 99% accuracy on MedDRA suggestions and cuts manual coding effort by roughly half.

These gains compound across every study that currently resets its institutional coding knowledge at each dictionary up-version or team turnover.

Our analysis suggests that if these accuracy levels hold at scale, they could dramatically reduce the time and cost associated with clinical data cleaning, a process that remains heavily reliant on spreadsheets and manual listing checks even as trial volumes grow.

Each of the three capabilities attacks a different bottleneck in clinical data review.

IQD allows a data manager to define any clinical or operational question in plain terms, without requiring code or a vendor change request.

The system applies that logic continuously, returning only records that need attention.

MSR replaces static spreadsheet-driven medical and safety reconciliation with a change-based, patient-centric workflow that posts queries directly back to the EDC, removing the handoff between Medical, Safety, and Data Management—a handoff that typically introduces the longest delays.

IMC, as noted, targets the coding bottleneck with high precision.

The co-innovation partner’s teams shaped both IQD’s user-defined scenario architecture and MSR’s change-based review model.

These capabilities are already running across the vast majority of that partner’s ongoing studies, including mega-studies, at launch.

This is not a pilot or a limited rollout—it is a full-scale deployment inside one of the world’s largest drug developers.

The regulatory timing is not incidental. ICH E6(R3) was finalized in January 2025, with the EMA making it effective July 23, 2025, and the FDA publishing it in September 2025.

The guidance formally encodes risk-based quality management principles that CluePoints’ earlier RBQM platform helped establish in practice.

Extending the same statistical and scientific foundation into query management, medical review, and coding now connects a sponsor’s data oversight workflow end-to-end under a single framework the guideline already recognizes, rather than requiring teams to reconcile outputs across disconnected systems before acting.

One practical implication for small and mid-size biotechs is that MSR deploys in days and works across ongoing studies, not just new ones.

This removes the typical barrier of waiting for a clean trial start.

For companies that lack the resources of a top-10 pharma, this could mean faster adoption of risk-based quality management without the upfront investment in custom development.

What should ordinary people—including patients and trial participants—take away from this?

The promise is that more accurate and efficient data review could lead to faster identification of safety signals and more reliable trial results.

For smaller companies, the actionable step is to evaluate whether these tools can integrate with their existing EDC systems and whether the cost of adoption is justified by the potential reduction in manual effort and coding errors.

The practical test of whether that speed holds at scale will be visible when the unnamed partner presents its production results at SCDM 2026.

Until then, the industry will be watching closely to see if the claims of 99% accuracy and half-cut manual effort survive real-world scrutiny.

Source: The Clinical Trial Vanguard, Moe Alsumidaie. Original source: CluePoints press release.